Know Cancer

or
forgot password

Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies


N/A
2 Years
N/A
Open (Enrolling)
Both
Hematologic Disease, Hematologic Neoplasm, Pancytopenia

Thank you

Trial Information

Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies


This protocol is designed to allow the evaluation, follow up, and standard medical care of
patients (and when appropriate, their stem cell donor) with bone marrow failure states,
cytopenias, metastatic solid tumors, or hematologic malignancies not currently entered on an
active NHLBI Hematology Branch protocol or not being screened for an active NHLBI research
protocol. Its purpose is to allow investigation into the hematologic problems of these
patients for the primary purpose of teaching and furthering general hematologic knowledge.
The ability to evaluate and treat patients with a wide variety of hematologic disease is
critical to maintaining our accreditation as a hematology fellowship program and training
our fellows to be competent hematologists, as well as for keeping all staff, including
senior staff, up-to-date and familiar with the evaluation and treatment of patients with a
wide spectrum of hematologic disease. It also allows the Hematology Branch to evaluate
patients referred with rare or as yet undiagnosed hematologic problems, both potentially
benefiting the patient and stimulating new research directions for the Hematology Branch in
the future. Periodic follow-up and treatment of patients previously entered on Hematology
Branch protocols in order to monitor the long-term course of the underlying hematologic
state and the consequences of experimental treatments is also required for fellowship
training, and for maintenance of good referral relationships with patients and their
physicians.

Inclusion Criteria


- INCLUSION CRITERIA:

Patients (and when appropriate the patient's stem cell donor) may be entered on this
protocol at the discretion of the Principal and/or Associate Investigators if :

An investigator decides that it is in the best interest of the patient/donor and the
Branch for the patient to be enrolled in this protocol while awaiting a decision on
eligibility for other protocols; or after enrollment on another protocol, or to allow
careful evaluation of patients with unique or rare disorders of direct interest to the
Branch; or with more common disorders for fellowship teaching purposes.

The patient or the patient's guardian is capable of informed consent and signs the consent
form. The consent form will be signed by parents or guardians of patients under the age
of 18.

Age greater than or equal to 2 and weight greater than 12 kg.

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

A. John Barrett, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Heart, Lung, and Blood Institute (NHLBI)

Authority:

United States: Federal Government

Study ID:

940010

NCT ID:

NCT00001397

Start Date:

October 1993

Completion Date:

Related Keywords:

  • Hematologic Disease
  • Hematologic Neoplasm
  • Pancytopenia
  • Hematologic Malignancies
  • Neoplasms
  • Hematologic Diseases
  • Pancytopenia
  • Hematologic Neoplasms

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892